Skip to content

Photobiomodulation Therapy in the treatment of Tinnitus

Effects of Photobiomodulation Therapy in the treatment of Tinnitus

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-2dwdry5
Enrollment
30
Registered
2026-05-04
Start date
2025-09-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tinnitus Hearing

Interventions

It is a prospective, analytical intervention study with a convenience sample. Participants aged over 18 years, receiving care at the Audiology Sector of the Speech-Language Pathology Teaching Clinic (
Evaluation of auditory function (otoscopy, immittance testing—tympanometry to identify type “A” tympanometric curve, conventional pure-tone audiometry, and high-frequency audiometry)
Tinnitus assessment (acuphenometry—to identify psychoacoustic measures of tinnitus, assist in perceptual evaluation, and contribute to treatment, including identification of tinnitus sound type and an

Sponsors

Universidade do Estado da Bahia
Lead Sponsor
Universidade do Estado da Bahia
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Aged 18 years or older; both genders; present a pure-tone average = 50 dB HL; and report constant tinnitus for at least six months; Individuals currently using ototoxic medication will be excluded from the study

Exclusion criteria

Exclusion criteria: Participants will be excluded if they present neurological or cognitive impairments that prevent adequate understanding of the study procedures; a history of acute or chronic otologic disorders; tympanic membrane perforation or otorrhea; history of meningitis; conductive or mixed hearing loss; somatosensory tinnitus influenced by temporomandibular disorders (TMD); or if they have undergone any specific tinnitus treatment within the month prior to study enrollment. Individuals presenting any contraindication to photobiomodulation therapy will also be excluded, including tumors or neoplasms, pacemakers or other electronic implants, pregnancy, use of retinoic acid or vitamin A derivatives (retinoic acid, retinol A, tretinoin, isotretinoin), antibiotic therapy with tetracycline, history of photosensitivity, use of anticoagulant medication, or history of thrombosis

Design outcomes

Primary

MeasureTime frame
The primary outcome will be tinnitus-related handicap measured by the Tinnitus Handicap Inventory (THI). Assessments will be conducted at baseline (prior to intervention), immediately after the final intervention session, and 15 days after the completion of treatment.

Secondary

MeasureTime frame
Secondary outcomes will include tinnitus intensity measured by acuphenometry and tinnitus-related discomfort measured using the Visual Analog Scale (VAS). These measures will be assessed at baseline (prior to intervention), immediately after the final intervention session, and 15 days after the completion of treatment.

Countries

BR

Contacts

Public ContactMara Rissatto-Lago

Universidade do Estado da Bahia

mrisatto@uneb.br+55-71-31172200

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Jun 11, 2026